64 related articles for article (PubMed ID: 19860591)
21. Zoledronate facilitates large-scale ex vivo expansion of functional gammadelta T cells from cancer patients for use in adoptive immunotherapy.
Kondo M; Sakuta K; Noguchi A; Ariyoshi N; Sato K; Sato S; Sato K; Hosoi A; Nakajima J; Yoshida Y; Shiraishi K; Nakagawa K; Kakimi K
Cytotherapy; 2008; 10(8):842-56. PubMed ID: 19016372
[TBL] [Abstract][Full Text] [Related]
22. Dendritic cell vaccine immunotherapy of cancer targeting MUC1 mucin.
Kontani K; Taguchi O; Ozaki Y; Hanaoka J; Sawai S; Inoue S; Abe H; Hanasawa K; Fujino S
Int J Mol Med; 2003 Oct; 12(4):493-502. PubMed ID: 12964025
[TBL] [Abstract][Full Text] [Related]
23. Superior antitumor in vitro responses of allogeneic matched sibling compared with autologous patient CD8+ T cells.
Kausche S; Wehler T; Schnürer E; Lennerz V; Brenner W; Melchior S; Gröne M; Nonn M; Strand S; Meyer R; Ranieri E; Huber C; Falk CS; Herr W
Cancer Res; 2006 Dec; 66(23):11447-54. PubMed ID: 17145892
[TBL] [Abstract][Full Text] [Related]
24. Generation of cytotoxic T lymphocytes against autologous lung cancer cells resistant to apoptosis.
Hiraki A; Ono T; Tanaka M; Kiura K; Ueoka H; Kawai H; Harada M; Nakayama E; Noguchi Y
Anticancer Res; 2001; 21(4A):2561-7. PubMed ID: 11724322
[TBL] [Abstract][Full Text] [Related]
25. Differential development of CD4 and CD8 cytotoxic T cells (CTL) in PBMC across the leprosy spectrum; IL-6 with IFN-gamma or IL-2 generate CTL in multibacillary patients.
de la Barrera S; Finiasz DM; Fink S; Valdez R; Bottasso O; Balina LM; Sasiain MC
Int J Lepr Other Mycobact Dis; 1997 Mar; 65(1):45-55. PubMed ID: 9207753
[TBL] [Abstract][Full Text] [Related]
26. Generation of MUC1-stimulated mononuclear cells using optimized conditions.
Wright SE; Khaznadar R; Wang Z; Quinlin IS; Rewers-Felkins KA; Phillips CA; Patel S
Scand J Immunol; 2008 Jan; 67(1):24-9. PubMed ID: 18021186
[TBL] [Abstract][Full Text] [Related]
27. Retention of immunogenicity produced by mucin 1 peptides with glycosylation site substitutions.
Wright SE; Quinlin IS; Rewers-Felkins KA; Dombrowski KE; Phillips CA
Immunopharmacol Immunotoxicol; 2010 Dec; 32(4):647-55. PubMed ID: 20470225
[TBL] [Abstract][Full Text] [Related]
28. Modifying interleukin-2 concentrations during culture improves function of T cells for adoptive immunotherapy.
Besser MJ; Schallmach E; Oved K; Treves AJ; Markel G; Reiter Y; Schachter J
Cytotherapy; 2009; 11(2):206-17. PubMed ID: 19148842
[TBL] [Abstract][Full Text] [Related]
29. Human cytotoxic T-cell lines with restricted specificity for squamous cell carcinoma of the head and neck.
Yasumura S; Hirabayashi H; Schwartz DR; Toso JF; Johnson JT; Herberman RB; Whiteside TL
Cancer Res; 1993 Mar; 53(6):1461-8. PubMed ID: 8443824
[TBL] [Abstract][Full Text] [Related]
30. [The repetitive immune cell transfer therapy combining non-myelosuppressive chemotherapy for patients with advanced and refractory cancer].
Toh U; Fujii T; Tayama K; Yanaga H; Yokoyama G; Yamaguchi M; Horiuchi H; Sasatomi T; Takamori S; Shirouzu K; Seki N; Yamana H
Gan To Kagaku Ryoho; 2004 Oct; 31(11):1649-51. PubMed ID: 15553672
[TBL] [Abstract][Full Text] [Related]
31. Immunization of chimpanzees with tumor antigen MUC1 mucin tandem repeat peptide elicits both helper and cytotoxic T-cell responses.
Barratt-Boyes SM; Vlad A; Finn OJ
Clin Cancer Res; 1999 Jul; 5(7):1918-24. PubMed ID: 10430099
[TBL] [Abstract][Full Text] [Related]
32. Increased non-major histocompatibility complex-restricted lytic activity in melanoma patients vaccinated with cytokine gene-transfected autologous tumor cells.
Möller P; Möller H; Sun Y; Dorbic T; Henz BM; Wittig B; Schadendorf D
Cancer Gene Ther; 2000 Jul; 7(7):976-84. PubMed ID: 10917199
[TBL] [Abstract][Full Text] [Related]
33. Breast carcinoma cell lysate-pulsed dendritic cells cross-prime MUC1-specific CD8+ T cells identified by peptide-MHC-class-I tetramers.
Bohnenkamp HR; Coleman J; Burchell JM; Taylor-Papadimitriou J; Noll T
Cell Immunol; 2004; 231(1-2):112-25. PubMed ID: 15919376
[TBL] [Abstract][Full Text] [Related]
34. Feasibility and safety of adoptive immunotherapy with ex vivo-generated autologous, cytotoxic T lymphocytes in patients with solid tumor.
Montagna D; Turin I; Schiavo R; Montini E; Zaffaroni N; Villa R; Secondino S; Schiavetto I; Caliogna L; Locatelli F; Libri V; Pession A; Tonelli R; Maccario R; Siena S; Pedrazzoli P
Cytotherapy; 2012 Jan; 14(1):80-90. PubMed ID: 21942841
[TBL] [Abstract][Full Text] [Related]
35. Cytotoxic T lymphocytes derived from bone marrow mononuclear cells of multiple myeloma patients recognize an underglycosylated form of MUC1 mucin.
Noto H; Takahashi T; Makiguchi Y; Hayashi T; Hinoda Y; Imai K
Int Immunol; 1997 May; 9(5):791-8. PubMed ID: 9184925
[TBL] [Abstract][Full Text] [Related]
36. Cytotoxic T lymphocytes from humans with adenocarcinomas stimulated by native MUC1 mucin and a mucin peptide mutated at a glycosylation site.
Wright SE; Kilinski L; Talib S; Lowe KE; Burnside JS; Wu JY; Dolby N; Dombrowski KE; Lebkowski JS; Philip R
J Immunother; 2000 Jan; 23(1):2-10. PubMed ID: 10687132
[TBL] [Abstract][Full Text] [Related]
37. [Development of specific immunotherapy for cancer].
Fujimoto S; Araki K; Hamasato S; Maeda N; Noguchi Y
Hum Cell; 1992 Sep; 5(3):247-55. PubMed ID: 1467324
[TBL] [Abstract][Full Text] [Related]
38. Anti-MUC1 class I restricted CTLs in metastatic breast cancer patients immunized with a synthetic MUC1 peptide.
Reddish M; MacLean GD; Koganty RR; Kan-Mitchell J; Jones V; Mitchell MS; Longenecker BM
Int J Cancer; 1998 Jun; 76(6):817-23. PubMed ID: 9626347
[TBL] [Abstract][Full Text] [Related]
39. Adoptive immunotherapy for advanced cancer patients using in vitro activated cytotoxic T lymphocytes.
Soda H; Koda K; Yasutomi J; Oda K; Takiguchi N; Saito N; Nakajima N
J Surg Oncol; 1999 Dec; 72(4):211-7. PubMed ID: 10589036
[TBL] [Abstract][Full Text] [Related]
40. Long-term survival after adoptive bone marrow T cell therapy of advanced metastasized breast cancer: follow-up analysis of a clinical pilot trial.
Domschke C; Ge Y; Bernhardt I; Schott S; Keim S; Juenger S; Bucur M; Mayer L; Blumenstein M; Rom J; Heil J; Sohn C; Schneeweiss A; Beckhove P; Schuetz F
Cancer Immunol Immunother; 2013 Jun; 62(6):1053-60. PubMed ID: 23595207
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
